The goal of the BPCA Program is to improve pediatric therapeutics through preclinical and clinical drug trials that lead to drug labeling changes.
Only 25 years ago, it was rare to find drug labels with dispensing information specific to children because pharmaceutical companies rarely conducted the research necessary to develop such instructions. As a result, health care providers often gave children smaller doses of adult medicines, without evidence to support those decisions.
For decades, NICHD has led a nationwide initiative to include infants, children, and adolescents in drug research studies to define how drugs approved for adults can be used safely and appropriately to treat children. NICHD leads the NIH’s activities related to the BPCA.
http://bpca.nichd.nih.gov/ for more information.